Patent Grant
10849540
This invention was not made with any government support, and the government has no rights in the invention.
The present disclosure pertains to the field of sensing target analytes in real time and in situ.
It is difficult to detect the presence of a target analyte directly either in a sample (e.g., in situ) or inside a body (e.g., in vivo). Currently, target analytes are detected by removing a sample and submitting such sample to a laboratory for analysis. It is also difficult to detect the target analyte in real time. Current techniques require a sample to be taken from a patient and then analyzed in a laboratory which greatly delays the timing of any diagnosis or detection of possibly toxic analytes. There is a need for a sensor with improved sensing characteristics and real-time in vivo/in situ detection capability. It would be further beneficial to have a sensor capable of rapid differentiation between viral and bacterial infections, and, if bacterial, segmentation into either Gram-positive or Gram-negative bacteria.
Disclosed herein is a biosensor for detecting the presence of a target analyte.
In a first aspect, a biosensor includes: a transducer component comprising an electrode operatively connected to a microprocessor, the microprocessor being adapted to receive, process and transmit a signal; and, a receptor component having: i) a sensing element capable of detecting and binding to at least one target analyte present in a sample; and, ii) a self-assembled monolayer (SAM), the SAM being positioned between and in contact with the sensing element and the electrode. The transducer component and the receptor component are capable of being brought into direct contact with the sample in situ. In use, the sensing element, in the presence of target analyte present in the sample, causes a detectable signal capable of being transmitted to the electrode via the SAM.
In certain embodiments, the presence of the target analyte is detected in real time.
In certain embodiments, the sensing element comprises at least one antibody capable of detecting at least one bacterial target analyte.
In certain embodiments, the sample comprises a fluid or tissue in a living organism. In certain embodiments, the sample comprises a fluid or tissue in a living organism in vivo. In certain embodiments, the sample comprises a fluid or tissue in a living animal. In certain embodiments, wherein the sample comprises a fluid or tissue in a human.
In certain embodiments, the sample comprises a food product.
In certain embodiments, the rate and degree of signal change correspond to the presence and concentration of the target analyte.
In certain embodiments, the presence of the target analyte is detected by impedance signal. In certain embodiments, the detectable signal comprises a change in impedance as a function of frequency.
In certain embodiments, the presence of the target analyte is detected by amperometric or potentiometric signal.
In certain embodiments, the electrode comprises a micro-interdigitated gold electrode.
In certain embodiments, the detectable signal is displayed on the microprocessor through radio frequency identification (RFID).
In certain embodiments, the biosensor is integrated into a medical, dental, or veterinary device having a tissue-contacting surface.
In certain embodiments, the target analyte comprises Staphylococcus aureus. In certain embodiments, the target analyte comprises methicillin-resistant Staphylococcus aureus (MRSA).
In certain embodiments, the target analyte comprises Streptococcus pyogenes, Streptococcus pneumoniae, or Streptococcus agalactiae.
In certain embodiments, the target analyte comprises a virus, or portion thereof.
In certain embodiments, the target analyte comprises a molecule, or portion thereof, that is a marker for a cancer.
In certain embodiments, the SAM comprises mercaptoproprionic acid (MPA), 11-mercaptoundecanoic acid (MUA), 1-tetradecanethiol (TDT), or dithiobios-N-succinimidyl propionate (DTSP).
In another aspect, there is provided herein a kit comprising the biosensor device described herein.
In another aspect, there is provided herein a method of making a biosensor capable of detecting a target analyte in situ in a sample. The method generally includes linking a sensing element to an electrode via a self-assembled monolayer (SAM); and operatively connecting a microprocessor to the electrode such that, when the sensing element binds to a target analyte present in situ in a sample, the microprocessor detects and transmits a signal.
In another aspect, there is provided herein a method of detecting a bacterial infection in a living organism, which includes placing the biosensor device described herein at least partially in or on the living organism sufficient to come into contact with any bacterial target analyte present in the living organism; and, detecting the presence of the bacterial target analyte when the biosensor device transmits the detectable signal.
In certain embodiments, the biosensor device determines whether the bacterial target analyte is Gram-positive or Gram-negative, and the biosensor device transmits a signal to the medical instrument indicating whether the bacterial target analyte is Gram-positive or Gram-negative.
In certain embodiments, the change in the physical properties of the sensing matrix that is detected comprises the change in impedance as a function of frequency.
The biosensor may be adapted and incorporated into any of several suitable medical instruments or surgical tools, including on the flexible tip of an elongated medical instrument. In certain embodiments, the sensing element comprises antibodies, and the sensor is adapted to detect the presence of a bacteria.
Further provided herein is a method of detecting the presence and/or determining the amount of bacteria present in a body.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not intended to limit the scope of the current teachings. In this application, the use of the singular includes the plural unless specifically stated otherwise.
The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”
Also, the use of “comprise”, “contain”, and “include”, or modifications of those root words, for example but not limited to, “comprises”, “contained”, and “including”, are not intended to be limiting. The term “and/or” means that the terms before and after can be taken together or separately. For illustration purposes, but not as a limitation, “X and/or Y” can mean “X” or “Y” or “X and Y”.
Throughout the entire specification, including the claims, the word “comprise” and variations of the word, such as “comprising” and “comprises” as well as “have,” “having,” “includes,” and “including,” and variations thereof, means that the named steps, elements, or materials to which it refers are essential, but other steps, elements, or materials may be added and still form a construct within the scope of the claim or disclosure. When recited in describing the invention and in a claim, it means that the invention and what is claimed is considered to be what follows and potentially more. These terms, particularly when applied to claims, are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.
Various embodiments are described herein in the context of apparatus, method, system, and/or process for sensing target analytes, such as bacteria or viruses or portions thereof. Those of ordinary skill in the art will realize that the following detailed description of the embodiments is illustrative only and not intended to be in any way limiting. Other embodiments will readily suggest themselves to such skilled persons having the benefit of this disclosure. Reference to an “embodiment,” “aspect,” or “example” herein indicate that the embodiments of the invention so described may include a particular feature, structure, or characteristic, but not every embodiment necessarily includes the particular feature, structure, or characteristic. Further, repeated use of the phrase “in one embodiment” does not necessarily refer to the same embodiment, although it may.
In the interest of clarity, not all of the routine features of the implementations or processes described herein are shown and described. It will be appreciated that numerous implementation-specific adaptations are incorporated to achieve specific goals, such as compliance with application- and business-related constraints, and that these specific goals vary from one implementation to another and from one developer to another. Moreover, it will be appreciated that such a development effort might be complex and time-consuming, but would nevertheless be a routine undertaking for those of ordinary skill in the art having the benefit of this disclosure.
Described herein is a biosensor device for detecting the presence and/or determining the amount of a target analyte in situ and in real time.
Referring first to a schematic representation of one embodiment of a biosensor device shown in
Referring now to
The transducer component 130 is comprised of at least one electrode 132, and at least one microprocessor 134. The microprocessor 134 is adapted to transmit and process a signal, as further explained herein. It is to be understood that the microprocessor 134 can include the generating an electronic image for review by a skilled person.
In certain embodiments, the biosensor device 110 can include more than one transducer component 130. In such embodiments, each electrode 132 is operatively connected to a corresponding microprocessor 134.
The receptor component includes one sensing (or receptor) element, 122 and a self-assembled monolayer (SAM) 124. The sensing element 122 is capable of detecting and binding to at least one target analyte 140. The self-assembled monolayer (SAM) 124 is positioned between and is in contact with both the sensing element 122 and the electrode 132. The sensing element 122, in the presence of the target analyte 140, causes a detectable signal capable of being transmitted to the electrode 132.
When the sensing element 122 contacts a sample 142 (for example, a fluid or tissue), and binds to the target analyte 140 that is present in the sample 142, a change in at least one physical property is detected by the electrode 132, and is transmitted as a signal by the microprocessor 134. As further described herein, in certain embodiments, the change in the physical property that is detected comprises the change in impedance as a function of frequency.
In certain embodiments, at least one of the entire instrument 500, the biosensor device 501/510, the handle end 502, and/or the distal probe end 506 can be disposable and/or configured to be attached and used in a sterile condition.
In certain embodiments, the annular opening 504 can also be configured to contain an RFID 514 for transmitting the detected signal. In addition, the instrument 500 can include a display 520 that is operatively connected to the microprocessor 508. The display 520 can be configured to display different types of information; for example, “+” or “−”, type of target analyte present, quantitative amount of analyte present, and the like.
In certain embodiments, as schematically illustrated in
Referring back to
In certain embodiments, the three electrode system (working 152, counter 154 and reference 156 electrodes) are useful for the electrochemistry analysis of a reaction causing electrical current flow. The binding reaction occurs on the working electrode 152. The counter electrode 154 and the reference electrode 156 generate electrical potentials against other potentials to be measured.
It is to be understood that the biosensor device can be configured to compensate for any noise at the time of the sampling where post-processing can include an algorithm that is applied through a software program to remove random noise, slopes, and the like.
It is also to be understood that the following can be determined experimentally by characterizing one or more of, for example: electrode size, drive voltage, environmental conditions such as temperature, analyte binding concentration, and the like.
The biosensor device can be configured to be adapted for use on small (e.g., nanoscale) samples. Also, the receptor component 120 can be configured to have different sensing elements 122 that can be clustered or arrayed for use in detection of multiple target analytes 140.
Receptors
Non-limiting examples of “receptor” can include an antibody, an antibody fragment, an aptamer, or an enzyme, or portions thereof.
The term “antibody” or “antibodies” as used herein refers to proteins used by the immune system to identify and/or neutralize foreign targets such as bacteria or viruses. Antibodies tend to be Y-shaped glycoproteins produced by B-cells and secreted by plasma cells. Antibodies recognize particular parts of a target known as antigens and bind to a specific epitope thereon. “Antibody” can be used interchangeably with “immunoglobulin” and is meant to include all known isotypes and natural antibodies.
In certain embodiments, the sensing element comprises antibodies specific for a target analyte to be sensed, such as Staphylococcus aureus antibodies in a sensor designed to detect the presence of Staphylococcus aureus. The antibodies can be synthesized or bought commercially.
In certain embodiments, the biosensor device can calibrated to both detect and quantify an amount of a target analyte present.
Electrodes
As used herein, “electrode” generally includes a composition, which, when connected to an electronic device, is able to sense a current or charge and convert it to a signal. Alternatively, an electrode can be a composition which can apply a potential to and/or pass electrons to or from connected devices.
Different electrodes include, but are not limited to, certain metals and their oxides, including gold; platinum; palladium; silicon; aluminum; metal oxide electrodes including platinum oxide, titanium oxide, tin oxide, indium tin oxide, palladium oxide, silicon oxide, aluminum oxide, molybdenum oxide (Mo2O6), tungsten oxide (WO3) and ruthenium oxides; and carbon (including glassy carbon electrodes, graphite and carbon paste). In one embodiment, the electrode can be a micro interdigitated gold electrode (MIGE).
Self-Assembled Monolayers (SAM) Layers
In the embodiments herein, the SAM layer 124 generally comprises a surface deposit on a surface of the electrode 132. Depending on the target analyte 140 to be detected, the SAM layer 140 that can substantially cover, or can partially cover, an area on the surface of the electrode 132. The SAM layer 124 generally comprises one or more organic molecules such that the SAM molecules act as a linker between the sensing element 122 and the electrode 132.
As one non-limiting example, a SAM is formed with mercaptoproprionic acid (MPA), which is readily bound with the amino group in certain antibodies via covalent bonding. In other non-limiting embodiments, a SAM is made from 11-mercaptoundecanoic acid (MUA), 1-tetradecanethiol (TDT), or dithiobios-N-succinimidyl propionate (DTSP). One suitable method of making and characterizing a monolayer is described in chapter 6 of Electrochemistry—A Laboratory Textbook; A workbook for the 910 PSTAT mini, Barbara Zumbrägel, Metrohm Monograph, January, 2013, the disclosure of which is hereby incorporated by reference.
Detectable Signals
In one embodiment, biosensor device detects electrochemical signals that may comprise, for example, conductivity signals, capacitance signals, impedance signals, potentiometric signals, or voltammetric signals. In embodiments comprising potentiometric sensors, a potential signal developed at the electrode/electrolyte surface is used to quantify the concentration of analyte present. In embodiments comprising voltammetric or amperometric sensors, a constant voltage signal is applied to the system and corresponding electrical current is used to quantify the analyte. Variable (linear or cyclic) voltage can be applied and the height of the peak in the current—voltage curve is used to quantify the analyte.
In some embodiments, the biosensor device utilizes electrochemical impedance spectroscopy, which measures impedance over a range of frequencies, to quantify the analyte. When a sine wave voltage is applied to a system, it produces a shifted sine wave current response. The impedance (Z) has two components: magnitude and phase shift (angle). This is illustrated in
The microprocessor processes the signals and eventually displays the information. Signal processing can generally include a series of microelectronic channels that screen the sensor signals and control the noise, calibration, and amplification.
In certain embodiments, the microprocessor program is composed to screen noise and to pick up impedance change at a very low frequency range; for example, from about 1 Hz to about 10 Hz.
The microprocessor includes an algorithm program capable of screening background noise and detecting up impedance signal that represent the presence and concentration of target analyte. The microprocessor program is composed to screen noise and to pick up impedance change at a very low frequency range. Also, in certain embodiments, the detectable signal can be displayed on the microprocessor through radio frequency identification (RFID).
Target Analytes
The term “target analyte” generally refers to any molecule that is detectable with a biosensor as described herein. Non-limiting examples of targets that are detectable in the biosensors described herein include, but are not limited to, biomolecules such as bacteria, viruses, proteins, nucleic acids, microRNAs, carbohydrates, and other types of small molecules such as microRNAs, and other such molecules that may indicate the presence of an infection, a cancer, or toxic analyte.
It is to be understood that the target analytes that can be detected using the biosensor device described herein can be present in a sample that comprises tissue or fluid of a living organism. Non-limiting examples of tissue include soft tissue, hard tissue, skin, surface tissue, outer tissue, internal tissue, a membrane, fetal tissue and endothelial tissue.
The living organism can be a mammal and can include pet animals, such as dogs and cats; farm animals, such as cows, horses and sheep; laboratory animals, such as rats, mice and rabbits; poultry, such as chicken and turkeys; and, primates, such as monkeys and humans. In one embodiment, the mammal is human. It is also to be understood that the sample can comprise, for example, a surgical incision, an open wound, a closed wound, an organ, skin, skin lesions, membranes, in situ fluids such as blood, urine, and the like.
In other embodiments, the sample can be a food source that could be contaminated by toxic organisms. Non-limiting examples of food sources can be grains, beverages, milk and dairy products, fish, shellfish, eggs, commercially prepared and/or perishable foods for animal or human consumption (e.g., ground meat, salads, and the like).
The sample can also be food tissue such as a fruit, an edible plant, a vegetable, a leafy vegetable, a plant root, a soy product, dead animal tissue, meat, fish and eggs, where the presence of the target analyte is indicative spoilage.
In other embodiments, the sample can be in an external environment, such a soil, water ways, sludge, commercial effluent, and the like.
In some embodiments designed to detect bacteria, the presence of bacteria is detected as the bacterial antigens are bound to the antibodies. As a result of this interaction, the electrochemistry on the electrode changes. The rate and degree of change in the signal can be detected through one of several different methods. In one embodiment, where amperometric sensing is conducted, the current change due to the bacteria-antibody interaction is transmitted through the electrode. In another embodiment, where impedance sensing is conducted, wherein the impedance variation in the electrode is measured.
The biosensor device may be designed to detect any specific bacteria that may cause infection in bone structure by incorporating antibodies specific to the bacteria into the sensing matrix. Though certain embodiments described herein comprise antibodies specific for Staphylococcus aureus, the biosensor device can be also designed to detect any Gram-positive or Gram-negative bacteria, and rapidly differentiate between the two.
By way of non-limiting example, antibodies specific for bacteria such as methicillin-resistant Staphyloccus aureus (MRSA), Staphylococcus epidermis, Staphylococcus saprophyticus, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus agalactiae, Escherichia coli, Legionella pneumophila, Pseudomonas aeruginosa, Enterococcus faecalis, E. Coli, Listeria, Cyclospora, Salmonella enteritidis, Helicobacter pylori, Tubercle bacillus (TB), other Bacillus, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Sporohalobacter, Anaerobacter, Heliobacterium, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Cyanobacteria, green sulfur bacteria, Chloroflexi, purple bacteria, thermodesulfobacteria, hydrogenophilaceae, nitrospirae, Burkholderia cenocepacia, Mycobacterium avium, Mycobacterium leprae, Mycobacterium tuberculosis, Mycobacterium ulcerans, Lactobacillus, Lactococcus, Bordetella pertussis, Chlamydia pneumoniae, Chlamydia tracomatis, Chlamydia psittaci, Borrelia burgdorferi, Campylobacter jejuni, Francisella tularensis, Leptospira monocytogenes, Leptospira interrogans, Mycoplasma pneumoniae, Rickettsia rickettsii, Shigella sonnei, Traponema pallidum, Vibrio cholerae, Haemophilus influenzae, Neiserria meningitidis, or Yersinia pestis can be incorporated into the sensing matrix, thereby enabling the biosensor to detect and/or quantify any such bacteria.
The biosensor device, as described herein, has applications in human treatment, veterinary care of animals, sampling of food source, determination of the presence of pathogens in an external environment, and the like. There is a need for rapid, accurate, and affordable methods to detect the presence of pathogens. In some embodiments, the biosensor device directly detects a pathogen. In other embodiments the biosensor device detects the antibodies, or immune response, to a pathogen.
Some examples of serious pathological agents in felines include, but are not limited to, Bartonella henselae, Borrelia burgdorferi, Chlamydia psittaci, Dirofilaria immitis, Ehrlichia canis, Feline Calicivirus, Feline Coronavirus, Feline Herpesvirus, Feline Immunodeficiency Virus, Feline Leukemia Virus, Leptospira spp, Mycoplasma haemofelis, Panleukopenia Virus, Toxoplasma gondii, and West Nile Virus.
Canine pathogens include, but are not limited to, Canine Adenovirus, Canine Distemper Virus, Canine Herpesvirus, Bordetella bronchiseptica, Neospora Hughesi and Caninum, Anaplasma phagocytophilum, Rickettsia rickettsii, Anaplasma platys, Canine parainfluenza virus, Tritrichomonas foetus, Clostridium difficle, Cryptosporidium spp., Cryptosporidium felis, Mycobacterium spp., Salmonella spp., Giardia spp and Taenia spp.
Equine pathogens include, but are not limited to, Equine Herpes Virus, Equine Influenza A, Lawsonia intracellularis, Streptococcus equi, Equine Arteritis virus, Campylobacter jejuni, E. Coli, Shigella spp., Yersinia enterocolitica, Rhodococcus equi, West Nile and Leptospira spp.
Marine mammal pathogens include, but are not limited to, bacteria: Staph sp., Strep sp., Erysipelas rhusiopathiae, Bartonella, Coxiella, Chlamydia, Pseudomonas sp., Pseudomonas pseudomallei, Pseudomonas mallei, Klebsiella, E. coli, Salmonella sp., Clostridia perfringens and Enterococcus; viruses: Dolphin pox, seal pox, papilloma universal, papilloma manatee, canine adenovirus, influenza A and B, hepatitis A and B, Bovine enterovirus, Cosackivirus, encephalomyocarditis virus, Morbilliviruses, canine distemper virus, Bovine corona virus, Bovine rotavirus, universal herpes and echovirus; fungi: Aspergillus, Nocardia, Histoplasma, Blastomyces, Coccidioides immitis, Lacazia loboi, Saksenaea and Aphophysomyces.
Some examples of other analytes that can be detected include pesticides and/or toxins, such as: aflatoxins, arsenic, botulin, ciguatera toxin, cyanide, deoxynivalenol, dioxin, fungi, fumonisins, fusarium toxins, heavy metals, histadine, histamine, lead, marine toxins, mercury, mycotoxins, neurotoxin, nicotine, ochratoxin A toxins, patulin toxins, polychlorinated phenyls, pyrrolizidine alkaloids, ricin, scombrotoxins, shellfish toxin, tetrodotoxin, trichothecenes, zearelenone, and the combinations thereof.
Other target analytes may include food allergens, such as: almond, egg, gliadin, gluten, hazelnut, milk, peanut, soy residues and combinations thereof.
It is also to be understood that, in certain embodiments, the biosensor device can detect analytes over desired time duration. The duration can be a first pre-determined time interval and a least a second pre-determined time interval that are calculated. In certain embodiments, an analyte correlation value is calculated during the test time interval.
Certain embodiments of the present invention are defined in the Examples herein. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
Cyclic voltammetry was used for electrochemical characterization of the sensing matrix described herein. Cyclic voltammetry is an electrochemical technique based on electrical current measurement as a function of voltage. The technique involves a working electrode where redox reactions or adsorption occurs, a reference electrode as a constant potential reference, an auxiliary or counter electrode that completes the circuit, an electrolyte, and a potentiostat (voltage source).
Gold circuits deposited on a micro interdigitated electrode acted as a transducer. The sensing matrix comprised a SAM and was formed on a gold electrode as the working electrode. The working electrode, a reference electrode, and a counter electrode were placed in a glass flask that was filled with electrolytes. Voltage was changed at a pre-determined rate and range, and the corresponding current change was recorded.
The gold electrode with SAM was shown to have higher impedance than a bare gold electrode. The gold electrode with MPA SAM was shown to have higher impedance magnitude and a different phase shift than the bare gold electrode. These results are depicted in the impedance curves in
Different SAMs were tested. Specifically, four electrodes were compared: a bare gold electrode, a gold electrode with 3-MPA SAM, a gold electrode with 3-MPA and 11-MUA SAM, and a gold electrode with 11-MUA SAM. The gold electrode with 11-MUA SAM had not only the highest resistance, but also the highest impedance, and the most different phase shift trend.
Screen printed electrodes (SPE) were sonicated in ethanol (99.5%) for 10 minutes and dried in a desiccator. A SPE was connected to a potentiostat and immersed in a conditioning solution containing 1 mL ammonium acetate buffer in 10 mL H2O. Potential sweeping was performed from 0.6 V to −0.5 V for electrochemical conditioning of the gold electrode surface.
A self-assembled monolayer (SAM) was formed on the SPE gold surface. SPEs were soaked in a solution of 1 mM 11-mercaptoundecanoic acid (MUA) in ethanol for 12 hours and then rinsed with ethanol to remove unbounded 11-MUA molecules. The electrodes were then treated in a solution of 0.05 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) and 0.2 M N-hydroxysuccinimide (NHS) crosslinkers. After being rinsed and dried, a solution of 20 μg/mL of Staphylococcus antibody in a phosphate buffer solution (pH 7.2) was dropped on the electrode surface and then held still for 2 hour. The electrode was then rinsed with a phosphate buffer. In order to decrease non-specific adsorption, a solution of bovine serum albumin (BSA) in the phosphate buffer was used to block unreacted sites of the SAM.
Electrochemical impedance spectroscopy (EIS) was performed using the software interface of the potentiostat from 1 Hz to 100 kHz.
As shown in
Although a significant change in impedance was not seen within one minute of putting the chip into a bacteria sample, the slope of the impedance-frequency (Z-f) curve changed immediately when MRSA bacteria were present. Thus, the Z-f curve slope, rather than the impedance magnitude itself, can be used as the sensing signal for fast detection.
It is to be understood that, depending on the particular embodiment, the biosensor device can utilize any of several principles of detection. In certain other embodiments, the types of signals detected include electrochemical (based on electrical properties), photometric (based on light properties), calorimetric (based on temperature change), and piezoelectric (based on elastic deformation of crystals caused by electrical potential).
The biosensor device may also be adapted for use in and/or incorporated into a variety of medical instruments or surgical tools, including but not limited to: endoscopic imaging devices, harvesting devices, retractors such as Hohmann retractors, bone hooks, skin hooks, nerve hooks, tension devices, forceps, elevators, drill sleeves, osteotomes, spinal rongeurs, spreaders, gouges, bone files and rasps, bone awls, rib shears, trephines, suction tubes, taps, tamps, calipers, countersinks, suture passers, and probes.
The biosensor device described herein can deliver instantaneous, accurate sensing of a target analyte. In certain embodiments, the biosensor device can be fitted on a medical instrument adapted to check a human throat for the presence of Streptococcus. The biosensor device can be used by a physician or other medical personnel to determine whether a patient, such as a child patient, has a streptococcus infection by placing the tip of a medical instrument that includes the biosensor into the throat of the patient.
In other embodiments, the biosensor device can be adapted for use in a hip revision procedure, wherein a medical instrument comprising the biosensor device is inserted to check for an infection such as tuberculosis of bone. The biosensor device enables immediate infection detection in any part of the body without having to wait for cultures.
In intraoperative procedure, a method that can sense the infection leading to determination of the following procedure does not exist to date. For example, in hip surgery, the current method still does not give determination of infection. The aspiration of the hip joint has to be shipped to a medical laboratory for evaluation. It will also involve an additional procedure to the patient. Under such circumstances, the surgeon can apply the sensor for the first reading while opening the hit joint for implantation. The second reading can be taken after the implant has been removed. This is the major area where the infection can be present. Use of the biosensor device aids in determining if a temporary implant with antibiotic administration needs to be applied after a wash out or a definite implantation can be done.
In clinical practice, for out patients, the infection sensor can be directly brought into contact with infected sites, and the outcome can be read on the display immediately.
In clinical practice, for out patients, the sensor can be used to determine the pathogen on the swab of the infected area.
In day care and clinical practice, it is a standard procedure to take the aspiration of the joint for evaluation. The fluid can be exposed to the sensor on a specially designed syringe device or applied on the biosensor device.
In emerging economies, such as in Southeast Asia, six out of ten patients have TB. This biosensor device is especially useful as a non-invasive instrument to determine the TB infections in real-time.
Certain embodiments and uses of the biosensor device disclosed herein are defined in the examples herein. It should be understood that these examples, while indicating particular embodiments of the invention, are given by way of illustration only. From the above discussion and these examples, one skilled in the art can ascertain the essential characteristics of this disclosure, and without departing from the spirit and scope thereof, can make various changes and modifications to adapt the compositions and methods described herein to various usages and conditions. Various changes may be made and equivalents may be substituted for elements thereof without departing from the essential scope of the disclosure. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the disclosure without departing from the essential scope thereof.
This application is a national stage application filed under 35 U.S.C. § 371 of international application PCT/US14/23126, filed under the authority of the Patent Cooperation Treaty on Mar. 11, 2014, published; which claims priority to U.S. provisional patent application 61/775,939, filed under 35 U.S.C. § 111(b) on Mar. 11, 2013. The entire disclosures of all the aforementioned applications are expressly incorporated herein by reference for all purposes.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2014/023126 | 3/11/2014 | WO | 00 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2014/164654 | 10/9/2014 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 4209585 | Lloyd et al. | Jun 1980 | A |
| 4267270 | Stout | May 1981 | A |
| 4562157 | Lowe et al. | Dec 1985 | A |
| 4704353 | Humphries et al. | Nov 1987 | A |
| 4765341 | Mower | Aug 1988 | A |
| 4822566 | Newman | Apr 1989 | A |
| 4847193 | Richards et al. | Jul 1989 | A |
| 4883057 | Broderick | Nov 1989 | A |
| 4927502 | Reading et al. | May 1990 | A |
| 5063081 | Cozzette et al. | Nov 1991 | A |
| 5140393 | Hijikihigawa et al. | Aug 1992 | A |
| 5203327 | Schoendorfer et al. | Apr 1993 | A |
| 5482830 | Bogart et al. | Jan 1996 | A |
| 5492840 | Malmqvist et al. | Feb 1996 | A |
| 5601694 | Maley et al. | Feb 1997 | A |
| 5628890 | Carter | May 1997 | A |
| 5629213 | Kornguth et al. | May 1997 | A |
| 5722397 | Eppstein | Mar 1998 | A |
| 5834224 | Ruger et al. | Nov 1998 | A |
| 5869272 | Bogart et al. | Feb 1999 | A |
| 6013029 | Korf et al. | Jan 2000 | A |
| 6096497 | Bauer | Aug 2000 | A |
| 6107080 | Lennox | Aug 2000 | A |
| 6210551 | Osman et al. | Apr 2001 | B1 |
| 6267722 | Anderson et al. | Jul 2001 | B1 |
| 6322963 | Bauer | Nov 2001 | B1 |
| 6346376 | Sigrist et al. | Feb 2002 | B1 |
| 6346387 | Stewart et al. | Feb 2002 | B1 |
| 6375829 | Shevchenko et al. | Apr 2002 | B1 |
| 6436699 | Berggren et al. | Aug 2002 | B1 |
| 6503701 | Bauer | Jan 2003 | B1 |
| 6544729 | Sayler et al. | Apr 2003 | B2 |
| 6573107 | Bowen et al. | Jun 2003 | B1 |
| 6585663 | Coley et al. | Jun 2003 | B1 |
| 6602400 | Choong et al. | Aug 2003 | B1 |
| 6650919 | Edelberg et al. | Nov 2003 | B2 |
| RE38525 | Stanley et al. | Jun 2004 | E |
| 6751491 | Lew et al. | Jun 2004 | B2 |
| 6770190 | Milanovski et al. | Aug 2004 | B1 |
| 6787368 | Wong et al. | Sep 2004 | B1 |
| 6821529 | Nelson | Nov 2004 | B2 |
| 6846654 | Blackburn et al. | Jan 2005 | B1 |
| 6914279 | Lu et al. | Jul 2005 | B2 |
| 6942771 | Kayyem | Sep 2005 | B1 |
| 6967074 | Duffy et al. | Nov 2005 | B2 |
| 6977160 | Yanagawa et al. | Dec 2005 | B2 |
| 7052854 | Melker et al. | May 2006 | B2 |
| 7125660 | Stanton et al. | Oct 2006 | B2 |
| 7138121 | Spangler et al. | Nov 2006 | B2 |
| 7163788 | Tong | Jan 2007 | B2 |
| 7271007 | Weigl et al. | Sep 2007 | B2 |
| 7291496 | Holm-Kennedy | Nov 2007 | B2 |
| 7292349 | Miller et al. | Nov 2007 | B2 |
| 7309566 | Fulton et al. | Dec 2007 | B2 |
| 7309614 | Baird et al. | Dec 2007 | B1 |
| 7317216 | Holm-Kennedy | Jan 2008 | B2 |
| 7332314 | Chang et al. | Feb 2008 | B2 |
| 7349080 | Aklian | Mar 2008 | B2 |
| 7399585 | Gau | Jul 2008 | B2 |
| 7455756 | Choi et al. | Nov 2008 | B2 |
| 7473551 | Warthoe | Jan 2009 | B2 |
| 7521019 | Polak et al. | Apr 2009 | B2 |
| 7531002 | Sutton et al. | May 2009 | B2 |
| 7632633 | Iwai et al. | Dec 2009 | B2 |
| 7687258 | Maki | Mar 2010 | B1 |
| 7766862 | Gerber et al. | Aug 2010 | B2 |
| 7985384 | Yazawa et al. | Jul 2011 | B2 |
| 8067184 | Schwoebel et al. | Nov 2011 | B2 |
| 8106428 | Koh et al. | Jan 2012 | B2 |
| 8153445 | Chen et al. | Apr 2012 | B2 |
| 8158342 | Chen et al. | Apr 2012 | B2 |
| 8216797 | Schwoebel et al. | Jul 2012 | B2 |
| 8349604 | Mohapatra et al. | Jan 2013 | B2 |
| RE43978 | Holm-Kennedy | Feb 2013 | E |
| 8374796 | Fernandez | Feb 2013 | B2 |
| 8425492 | Herbert et al. | Apr 2013 | B2 |
| 8442611 | Santini, Jr. et al. | May 2013 | B2 |
| 8450056 | Miller et al. | May 2013 | B2 |
| 8486619 | Miller et al. | Jul 2013 | B2 |
| 8591459 | Clymer et al. | Nov 2013 | B2 |
| 8623196 | Kohli et al. | Jan 2014 | B2 |
| 8649840 | Sheppard, Jr. et al. | Feb 2014 | B2 |
| 8673626 | Chang et al. | Mar 2014 | B2 |
| 8834946 | Abramson et al. | Sep 2014 | B2 |
| 8841137 | DeLouise et al. | Sep 2014 | B2 |
| 8898069 | Hood et al. | Nov 2014 | B2 |
| 8900879 | Lin et al. | Dec 2014 | B2 |
| 8914090 | Jain et al. | Dec 2014 | B2 |
| 9029168 | McAlpine et al. | May 2015 | B2 |
| 9034638 | Miller et al. | May 2015 | B2 |
| 9097676 | Meinhart et al. | Aug 2015 | B2 |
| 9217745 | Miller et al. | Dec 2015 | B2 |
| 9267919 | Larkins et al. | Feb 2016 | B1 |
| 20030009097 | Sheraton | Jan 2003 | A1 |
| 20040146899 | Kayyem | Jul 2004 | A1 |
| 20060155174 | Glukhovsky | Jul 2006 | A1 |
| 20070179568 | Nycz | Aug 2007 | A1 |
| 20080200343 | Clemens | Aug 2008 | A1 |
| 20080204043 | Wang | Aug 2008 | A1 |
| 20090084686 | Yun et al. | Apr 2009 | A1 |
| 20090143659 | Li et al. | Jun 2009 | A1 |
| 20090184002 | Furukawa et al. | Jul 2009 | A1 |
| 20100116682 | Neuzil | May 2010 | A1 |
| 20100298679 | Wu et al. | Nov 2010 | A1 |
| 20100331771 | Mazza | Dec 2010 | A1 |
| 20110115499 | Chodavarapu | May 2011 | A1 |
| 20110189705 | Gao | Aug 2011 | A1 |
| 20110275912 | Boyden et al. | Nov 2011 | A1 |
| 20120088315 | Merelle et al. | Apr 2012 | A1 |
| 20120135509 | Hall | May 2012 | A1 |
| 20120209090 | Goodall | Aug 2012 | A1 |
| 20130053665 | Hughes et al. | Feb 2013 | A1 |
| 20130213823 | Arumugam | Aug 2013 | A1 |
| Number | Date | Country |
|---|---|---|
| 1443307 | Sep 2003 | CN |
| 101432625 | May 2009 | CN |
| Entry |
|---|
| Carrara et al., “Fully Integrated Biochip Platforms for Advanced Healthcare”, Sensors, 2012, vol. 12, pp. 11013-11060. |
| Geng et al., “Self-assembled monolayers-based immunosensor for detection of Escherichia coli using electrochemical impedance spectroscopy”, Electrochimica Acta 53, 2008, pp. 4663-4668. |
| Wang et al., “New Trends in Impedimetric Biosensors for the Detection of Foodbome Pathogenic Bacteria”, Sensors, 2012, vol. 12, pp. 3449-3471. |
| Wisniewski et al., “Methods for reducing biosensor membrane biofouling”, Colloids and Surfaces B: Biointerfaces, 2000, vol. 18, pp. 197-219. |
| Zheng, “The development of an aptamer-based surface plasmon resonance (SPR) sensor of the real-time detection of glycated protein”, The University of Toledo, Theses and Dissertation, 2012, pp. 1-206. |
| European Examination Report, Application No. EP14779197.4 dated Oct. 20, 2017. |
| Second Chinese Office Action, Application No. 201480026380.4, dated Jun. 13, 2017. |
| PCT International Search Report and the Written Opinion, Application No. PCT/US2014/023126 filed Mar. 11, 2014, dated Jul. 9, 2014. |
| Intellectual Property India, Examination report under sections 12 & 13 of the Patents Act, 1970 and the Patents Rules, 2003, Application No. 6073/CHENP/2015, dated Mar. 3, 2020. |
| Number | Date | Country | |
|---|---|---|---|
| 20160022185 A1 | Jan 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| 61775939 | Mar 2013 | US |
